Gow Chien-Hung, Wu Shang-Gin, Chang Yih-Leong, Shih Jin-Yuan
Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan.
Med Oncol. 2014 Jul;31(7):34. doi: 10.1007/s12032-014-0034-4. Epub 2014 Jun 10.
Several new chromosomal translocations resulting in driver fusion mutations have recently been discovered in non-small-cell lung cancer. The driver mutational patterns in pulmonary mucinous adenocarcinoma, a rare subtype of non-small-cell lung cancer, have not been well studied. A single-institute cohort study in Taiwan was performed to determine the mutations of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), fusions of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neuregulin 1 (NRG1) in patients diagnosed with pulmonary mucinous adenocarcinoma. We also examined NRG1 translocation in patients diagnosed as adenocarcinoma of other subtypes with wild-type EGFR, KRAS, ALK, and ROS1 genes. Surgical or biopsy specimens were collected from 13 patients with mucinous adenocarcinoma. Using the direct RNA sequencing method, we discovered a rare CD74-NRG1 fusion (8 %), an echinoderm microtubule-associated protein like 4 (EML4)-ALK fusion (17 %), and three KRAS mutations (25 %). No EGFR mutations or ROS1 rearrangements were detected. The rare CD74-NRG1 fusion positive patient presented with uncommon radiological features. We did not detect any CD74-NRG1 fusion in the 109 adenocarcinoma of other subtypes, which were all negative for EGFR, KRAS, ALK, and ROS1. The CD74-NRG1 fusion mutation is rare and may be exclusively present in patients with pulmonary mucinous adenocarcinoma. Patients harboring CD74-NRG1 positive tumors may present with uncommon imaging features.
最近在非小细胞肺癌中发现了几种导致驱动融合突变的新染色体易位。肺黏液腺癌是一种罕见的非小细胞肺癌亚型,其驱动突变模式尚未得到充分研究。台湾的一项单机构队列研究旨在确定诊断为肺黏液腺癌的患者中表皮生长因子受体(EGFR)、 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)、间变性淋巴瘤激酶(ALK)、 c-ros癌基因1(ROS1)和神经调节蛋白1(NRG1)的突变情况。我们还检测了诊断为其他亚型腺癌且EGFR、KRAS、ALK和ROS1基因野生型的患者中的NRG1易位。收集了13例黏液腺癌患者的手术或活检标本。使用直接RNA测序方法,我们发现了一种罕见的CD74-NRG1融合(8%)、一种棘皮动物微管相关蛋白样4(EML4)-ALK融合(17%)和三种KRAS突变(25%)。未检测到EGFR突变或ROS1重排。罕见的CD74-NRG1融合阳性患者表现出不常见的影像学特征。在109例其他亚型腺癌中未检测到任何CD74-NRG1融合,这些腺癌的EGFR、KRAS、ALK和ROS1均为阴性。CD74-NRG1融合突变罕见,可能仅存在于肺黏液腺癌患者中。携带CD74-NRG1阳性肿瘤的患者可能表现出不常见的影像学特征。